Recent progress in cannabinoid research.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Progress in Medicinal Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0079-6468(05)44406-9PMID 16697899
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.

  2006cited by this paper
• Hu 210: a potent tool for investigations of the cannabinoid system.

  2006cited by this paper
• Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice

  2005cited by this paper
• Heterocyclic sulfoxide and sulfone inhibitors of fatty acid amide hydrolase.

  2005cited by this paper
• Recent advances in the research and development of CB1 antagonists.

  2005cited by this paper
• Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.

  2005cited by this paper
• Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

  2005cited by this paper
• CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.

  2005cited by this paper
• Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats.

  2005cited by this paper
• Cannabinoids and the regulation of ingestive behaviour.

  2005cited by this paper
• Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity.

  2005cited by this paper
• The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile

  2005cited by this paper
• Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

  2005cited by this paper
• Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists.

  2005cited by this paper
• Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation.

  2005cited by this paper
• Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists.

  2005cited by this paper
• The anandamide membrane transporter and the therapeutic implications of its inhibition

  2005cited by this paper
• Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics.

  2005cited by this paper
• Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists.

  2005cited by this paper
• Evidence for novel cannabinoid receptors.

  2005cited by this paper
• Nicotine-Associated Cues Maintain Nicotine-Seeking Behavior in Rats Several Weeks after Nicotine Withdrawal: Reversal by the Cannabinoid (CB1) Receptor Antagonist, Rimonabant (SR141716)

  2005cited by this paper
• Preferred conformations of endogenous cannabinoid ligand anandamide.

  2005cited by this paper
• Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors.

  2005cited by this paper
• Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.

  2004cited by this paper
• 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects

  2004cited by this paper
• The role of halogen substitution in classical cannabinoids: A CB1 pharmacophore model

  2004cited by this paper
• Cannabinoids and glaucoma

  2004cited by this paper
• Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.

  2004cited by this paper
• Ajulemic acid: A novel cannabinoid produces analgesia without a "high".

  2004cited by this paper
• Behavioral effects of inhibition of cannabinoid metabolism: The amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide.

  2004cited by this paper
• 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.

  2004cited by this paper
• Recent advances in CB1 cannabinoid receptor antagonists.

  2004cited by this paper
• Recent advances in the cannabinoids

  2004cited by this paper
• The endocannabinoid system and its therapeutic exploitation

  2004cited by this paper
• Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury

  2004cited by this paper
• Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat.

  2004cited by this paper
• Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.

  2004cited by this paper
• Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors.

  2004cited by this paper
• Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist

  2004cited by this paper
• Development of a 3D model for the human cannabinoid CB1 receptor.

  2004cited by this paper
• Evidence that CB‐1 and CB‐2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat

  2004cited by this paper
• Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats.

  2004cited by this paper
• Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity

  2004cited by this paper
• The endocannabinoid system: a general view and latest additions

  2004cited by this paper
• Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif.

  2004cited by this paper
• Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.

  2004cited by this paper
• SR147778 [5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a New Potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization

  2004cited by this paper
• Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.

  2004cited by this paper
• Are oral cannabinoids safe and effective in refractory neuropathic pain?

  2004cited by this paper
• An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

  2004cited by this paper
• Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia‐reperfusion injury: involvement of cytokine/chemokines and PMN

  2004cited by this paper
• Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes.

  2004cited by this paper
• Metabolism of the endocannabinoids anandamide and 2-arachidonoyl glycerol, a review, with emphasis on the pharmacology of fatty acid amide hydrolase, a possible target for the treatment of neurodegenerative diseases and pain

  2004cited by this paper
• CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity

  2004cited by this paper
• (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only.

  2004cited by this paper
• Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues.

  2003cited by this paper
• Homologues and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat cannabinoid CB(1) receptors.

  2003cited by this paper
• Cannabinoids: mechanisms and therapeutic applications in the CNS.

  2003cited by this paper
• Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.

  2003cited by this paper
• SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task.

  2003cited by this paper
• Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.

  2003cited by this paper
• Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'.

  2003cited by this paper
• Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors.

  2003cited by this paper
• Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids.

  2003cited by this paper
• Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors.

  2003cited by this paper
• Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS

  2003cited by this paper
• Cannabinoid agonists attenuate capsaicin‐induced responses in human skin

  2003cited by this paper
• Structure–activity relationships for 1′,1′-dimethylalkyl-Δ 8 -tetrahydrocannabinols

  2003cited by this paper
• IACM 2nd Conference on Cannabinoids in Medicine

  2003cited by this paper
• Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor

  2003cited by this paper
• Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists.

  2003cited by this paper
• The molecular logic of endocannabinoid signalling

  2003cited by this paper
• The Cannabinoid CB1 Antagonist N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) Differentially Alters the Reinforcing Effects of Heroin under Continuous Reinforcement, Fixed Ratio, and Progressive Ratio Schedules of Drug Self-Administration in Rats

  2003cited by this paper
• Endogenous cannabinoid system as a modulator of food intake

  2003cited by this paper
• Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties.

  2003cited by this paper
• Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.

  2003cited by this paper
• Structure elucidation of a novel ring‐constrained biaryl pyrazole CB1 cannabinoid receptor antagonist

  2003cited by this paper
• Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

  2003cited by this paper
• Inhibition of guinea‐pig and human sensory nerve activity and the cough reflex in guinea‐pigs by cannabinoid (CB2) receptor activation

  2003cited by this paper
• Novel selective and metabolically stable inhibitors of anandamide cellular uptake.

  2003cited by this paper
• CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?

  2003cited by this paper
• The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

  2003cited by this paper
• Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

  2003cited by this paper
• Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.

  2003cited by this paper
• 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor.

  2003cited by this paper
• An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.

  2003cited by this paper
• Evidence against the presence of an anandamide transporter

  2003cited by this paper
• Ether‐linked analogue of 2‐arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species

  2003cited by this paper
• Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction

  2003cited by this paper
• Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after Δ9-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716

  2003cited by this paper
• Synthesis and testing of novel classical cannabinoids: exploring the side chain ligand binding pocket of the CB1 and CB2 receptors.

  2003cited by this paper
• Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.

  2003cited by this paper
• SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

  2002cited by this paper
• CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain

  2002cited by this paper
• 1-Methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Delta(8)-tetrahydrocannabinols: new selective ligands for the CB2 receptor.

  2002cited by this paper
• Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors.

  2002cited by this paper
• The fatty acid amide hydrolase (FAAH).

  2002cited by this paper
• Brain monoglyceride lipase participating in endocannabinoid inactivation

  2002cited by this paper
• Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide--targets for drug development?

  2002cited by this paper
• International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

  2002cited by this paper

• Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.

  2013cites this paper
• Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.

  2011cites this paper
• Design, synthesis, and structure-activity relationships of indole-3-heterocycles as agonists of the CB1 receptor.

  2011cites this paper
• Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.

  2011cites this paper
• Preparation and Characterization of Inclusion Complexes of a Hemisuccinate Ester Prodrug of Δ9-Tetrahydrocannabinol with Modified Beta-Cyclodextrins

  2010cites this paper
• Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists.

  2010cites this paper
• Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach.

  2010cites this paper
• Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.

  2010cites this paper
• Synthesis and Pharmacological Evaluation of Analogs of Indole‐Based Cannabimimetic Agents

  2010cites this paper
• Preparation and Characterization of Lyophilized Cyclodextrin Complexes of a Hemisuccinate Ester of Delta-9-Tetrahydrocannabinol for Transmucosal Delivery

  2010cites this paper
• The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies.

  2010cites this paper
• Novel benzimidazole derivatives as selective CB2 agonists.

  2008cites this paper
• Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.

  2008cites this paper
• New Natural Noncannabinoid Ligands for Cannabinoid Type-2 (CB2) Receptors

  2006influential citation